Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2021-06-14
- Target Recruit Count
- 35
- Registration Number
- NCT01842646
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2017-01-19
- Target Recruit Count
- 1
- Registration Number
- NCT01841021
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
COGNUTRIN in Breast Cancer Survivors
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2020-07-14
- Target Recruit Count
- 36
- Registration Number
- NCT01823991
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2016-01-18
- Target Recruit Count
- 15
- Registration Number
- NCT01822691
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Colorectal Cancer Awareness, Research, Education and Screening (CARES)
- Conditions
- Colorectal Cancer
- Interventions
- Other: Immunochemical Fecal Occult Blood Test (I-FOBT) KitOther: Standard Intervention (SI) Educational MaterialsOther: CARES Intervention Educational MaterialsOther: Baseline Visit SurveyOther: Follow-up Questionnaire
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2022-09-10
- Target Recruit Count
- 514
- Registration Number
- NCT01804179
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
- Conditions
- Graft Versus Host Disease
- Interventions
- Biological: Cultured Treg cells
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2022-11-03
- Target Recruit Count
- 38
- Registration Number
- NCT01795573
- Locations
- 🇺🇸
H Lee Moffitt Cancer Center, Tampa, Florida, United States
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2022-10-31
- Target Recruit Count
- 19
- Registration Number
- NCT01795586
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2022-09-22
- Target Recruit Count
- 50
- Registration Number
- NCT01776723
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2017-04-19
- Target Recruit Count
- 15
- Registration Number
- NCT01760499
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
GTX-RT in Borderline Resectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Radiation: Stereotactic body radiation therapy (SBRT)Other: Restaging review after radiationProcedure: Surgery
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2015-08-13
- Target Recruit Count
- 9
- Registration Number
- NCT01754623
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States